Peptinovo’s initial candidate, PNB-281 (PALM™ with Paclitaxel), is currently in preclinical testing and has initiated the necessary manufacturing and toxicology studies to move the compound to IND.  The Peptinovo team has developed three other leading chemotherapy drugs (Tubulin Disruptors, Platinum Drugs and Gemcitabine) leveraging the PALM™ Technology Platform.

Our goal is to begin first-in-human testing by Jan 2024 and complete Phase 1 trials by Q3 2024.

Robust Future Pipeline

The platform continues to build. On the pharmacology side, we have now demonstrated in vitro efficacy in several cell lines using one chemotherapy drug, Paclitaxel.  Additionally, we have demonstrated the ability of our nanoparticle technology to carry several other chemotherapy drugs (Tubulin Disruptors, Platinum drugs and Gemcitabine) and suppress cancer cell growth.